Information Provided By:
Fly News Breaks for July 27, 2018
QURE
Jul 27, 2018 | 08:02 EDT
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of uniQure with an Overweight rating and $58 price target. Given the previous success in hemophilia gene therapy trials along with the FDA stance, uniQure has the potential to be the leader in hemophilia B treatment, Piros tells investors in a research note. To the analyst's knowledge, the most competitive indication to be addressed by gene therapy is hemophilia. He believes the FDA is noticing too.
News For QURE From the Last 2 Days
There are no results for your query QURE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.